Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"EdiGene","sponsor":"3H Health Investment","pharmaFlowCategory":"D","amount":"$67.0 million","upfrontCash":"Undisclosed","newsHeadline":"EdiGene Raises Approximately USD 67 Million in Series B Financing to Advance Gene Editing Based Programs into Clinical Stage","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"},{"orgOrder":0,"company":"EdiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Approves EdiGene\u2019s IND Application of CRISPR\/Cas 9 Gene-Editing Therapy, ET-01 to Treat Transfusion Dependent \u00df-Thalassemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling"},{"orgOrder":0,"company":"EdiGene","sponsor":"University of Wisconsin\u2013Madison","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EdiGene Enters Research Collaboration with the University of Wisconsin-Madison on in Vivo RNA Editing Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery"},{"orgOrder":0,"company":"EdiGene","sponsor":"Haihe Laboratory","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EdiGene Enters Strategic R&D Collaboration with Haihe Laboratory of Cell Ecosystem to Develop Hematopoietic Stem Cell Regenerative Therapies and Platform Technologies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I"},{"orgOrder":0,"company":"EdiGene","sponsor":"Arbor Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EdiGene and Arbor Biotechnologies Announce Worldwide Non-exclusive License Agreement to Advance Ex Vivo Engineered Cell Therapy Programs","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform"},{"orgOrder":0,"company":"EdiGene","sponsor":"Neukio Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EdiGene and Neukio Enter Collaboration to Develop Next-Generation Immune Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"EdiGene","sponsor":"Peking University Cancer Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EdiGene Enters Research Collaboration With Peking University Cancer Hospital to Advance the Development of Targeted Therapy for Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"CHINA","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"}]

    Find Clinical Drug Pipeline Developments & Deals by EdiGene

    Menu

    EdiGene

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              EdiGene

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              EdiGene Enters Research Collaboration With Peking University Cancer Hospital to Advance the Development of Targeted Therapy for Colorectal Cancer

              Details:

              EdiGene’s high-throughput genome-editing screening platform uses high-throughput screening and bioinformatics analysis to develop new biomarkers and potential targeted therapies.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Peking University Cancer Hospital

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 13, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              EdiGene

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              EdiGene and Neukio Enter Collaboration to Develop Next-Generation Immune Cell Therapies

              Details:

              The collaboration will leverage EdiGene’s expertise in high-throughput genome editing screening and Neukio’s strength in the development and manufacturing of induced pluripotent stem cell (iPSC) and natural killer cell (NK Cell).

              Lead Product(s): iPSC-CAR-NK Cell Therapy

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Neukio Biotherapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration February 09, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              EdiGene

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              EdiGene and Arbor Biotechnologies Announce Worldwide Non-exclusive License Agreement to Advance Ex Vivo Engineered Cell Therapy Programs

              Details:

              Partnering with leading engineered cell therapy developers is a key component of Arbor’s strategy to broaden the potential of CRISPR discovery engine beyond the wholly-owned in vivo genetic medicine approaches for the benefit of even more patients.

              Lead Product(s): Ex-vivo Engineered Cell Therapy

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

              Recipient: Arbor Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement February 08, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              EdiGene

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              EdiGene Enters Strategic R&D Collaboration with Haihe Laboratory of Cell Ecosystem to Develop Hematopoietic Stem Cell Regenerative Therapies and Platform Technologies

              Details:

              Under the agreement, both parties will develop hematopoietic stem cell regenerative therapies, ET-01, including the development of genetically-modified hematopoietic stem cell therapies and exploration of novel biomarkers to optimize quality control for stem cell production.

              Lead Product(s): ET-01

              Therapeutic Area: Genetic Disease Product Name: ET-01

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Haihe Laboratory

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration January 24, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              EdiGene

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              EdiGene Enters Research Collaboration with the University of Wisconsin-Madison on in Vivo RNA Editing Therapies

              Details:

              Under the partnership, EdiGene will work with the David Gamm Laboratory to evaluate the pharmacological property of LEAPER™ RNA employs short engineered ADAR-recruiting RNAs (arRNAs) base editing candidates targeting specific genetic diseases.

              Lead Product(s): Short Engineered ADAR-recruiting RNAs

              Therapeutic Area: Genetic Disease Product Name: arRNAs

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: University of Wisconsin–Madison

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration November 09, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              EdiGene

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              China NMPA Approves EdiGene’s IND Application of CRISPR/Cas 9 Gene-Editing Therapy, ET-01 to Treat Transfusion Dependent ß-Thalassemia

              Details:

              ET-01 is an autologous, in vitro gene editing therapy product in the research and development stage. The clinical trial approved this time is a multi-center, open, single-arm clinical study.

              Lead Product(s): ET-01

              Therapeutic Area: Genetic Disease Product Name: ET-01

              Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 18, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              EdiGene

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              EdiGene Raises Approximately USD 67 Million in Series B Financing to Advance Gene Editing Based Programs into Clinical Stage

              Details:

              EdiGene has established four gene editing based platforms and is advancing its early stage programs into clinical development for patients with genetic diseases and cancer. Proceeds from the financing will be used to advance the company’s pipeline into clinics.

              Lead Product(s): ET-01

              Therapeutic Area: Genetic Disease Product Name: ET-01

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: 3H Health Investment

              Deal Size: $67.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing October 13, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY